<DOC>
	<DOCNO>NCT01101048</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability , potential immune response AMG 167 follow multiple subcutaneous ( SC , injection skin ) dose administration healthy men postmenopausal woman low bone mineral density .</brief_summary>
	<brief_title>An Ascending Multiple Dose Study Evaluating AMG 167 Healthy Men Postmenopausal Women With Low Bone Mineral Density</brief_title>
	<detailed_description />
	<mesh_term>Bone Diseases , Metabolic</mesh_term>
	<criteria>Low bone mineral density determine time screen [ define bone mineral density ( BMD ) Tscores lumbar spine ( L1L4 ) , total evaluable vertebra ( few L1L4 ) ; femoral neck 1.0 2.5 , exclusive ] 25hydroxyvitamin D ≥ 20 ng/mL Willing able take ≥ 1,000 mg elemental calcium ≥ 800 IU ( ≤ 1,000 IU ) vitamin D daily upon enrollment Osteoporosis , define BMD Tscores lumbar spine ( L1L4 ) total evaluable vertebra ( few L1L4 ) ; femoral neck ≤ 2.5 History vertebral fracture , fragility fracture ( fracture result minor trauma ; ie , fall stand height less ) wrist , humerus , hip , pelvis age 50 Diagnosed condition affect bone metabolism Diagnosis clot factor deficiency history bleed coagulation disorder History spinal stenosis History facial nerve paralysis Exclusion Criteria Cohort 7 Substudy ( Transition Alendronate ) : Contraindicated intolerant alendronate therapy</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Amgen</keyword>
	<keyword>Phase 1b</keyword>
	<keyword>Postmenopausal</keyword>
	<keyword>Bone Mineral Density</keyword>
</DOC>